Amarin Corp Plcuk (AMRN) EBITDA Margin (2013 - 2026)
Amarin Corp Plcuk (AMRN) reported EBITDA Margin of 25.11% for Q1 2026, up 1476.0% year-over-year from 1.59% in Q1 2025, and down 135.48% quarter-over-quarter from 70.77% in Q4 2025.
Amarin Corp Plcuk (AMRN) EBITDA Margin (2013 - 2026) Analysis & Trends
Amarin Corp Plcuk (AMRN) has 14 years of EBITDA Margin data on file, last reported at 25.11% in Q1 2026.
- EBITDA Margin for Q1 2026 came in at 25.11%, up 1476.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 1.66% (up 884.0% YoY), and the FY2025 annual result was 4.22%, up 422.0% from the prior year.
- EBITDA Margin slipped to 25.11% in Q1 2026 per AMRN's latest filing, from 70.77% in the prior quarter.
- Over five years, EBITDA Margin peaked at 70.77% in Q4 2025 and troughed at 66.53% in Q2 2022.
- A 5-year average of 12.95% and a median of 22.35% in 2025 frame the typical range for EBITDA Margin.
- The sharpest annual moves came in 2022 and 2023: EBITDA Margin tumbled 7221 bps in 2022, then jumped 7665 bps in 2023.
- A 5-year view of EBITDA Margin shows it stood at 10.62% in 2022, then surged by 722 bps to 66.03% in 2023, then plunged by 51 bps to 32.06% in 2024, then jumped by 121 bps to 70.77% in 2025, then sank by 135 bps to 25.11% in 2026.
- Business Quant data shows AMRN's EBITDA Margin at 25.11% in Q1 2026, 70.77% in Q4 2025, and 22.35% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 30.06% |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 47.98% |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 26.44% |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 26.60% |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | -47.46% |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 30.94% |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 37.16% |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | -286.83% |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 24.65% |
| 10 | Amarin Corp Plcuk | 5.84 Bn | 5.66 Bn | 17.77 Mn | -25.11% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -25.11% |
| Dec 31, 2025 | 70.77% |
| Sep 30, 2025 | -22.35% |
| Jun 30, 2025 | -21.98% |
| Mar 31, 2025 | -39.88% |
| Dec 31, 2024 | 32.06% |
| Sep 30, 2024 | -59.50% |
| Jun 30, 2024 | -0.78% |
| Mar 31, 2024 | -24.03% |
| Dec 31, 2023 | 66.03% |
| Sep 30, 2023 | -32.47% |
| Jun 30, 2023 | -29.89% |
| Mar 31, 2023 | -20.17% |
| Dec 31, 2022 | -10.62% |
| Sep 30, 2022 | -5.72% |
| Jun 30, 2022 | -66.53% |
| Mar 31, 2022 | -29.91% |
| Dec 31, 2021 | 5.85% |
| Sep 30, 2021 | -9.20% |
| Jun 30, 2021 | 5.68% |